
‘Postcode lottery' sees cancer patients face delays to treatment
The Royal College of Radiologists (RCR) has warned that these gaps in the cancer workforce are putting patient safety at risk.
Despite some increases in staffing, the college asserts that these are not keeping pace with the growing demand from patients.
The RCR has called on the government to take immediate action to address what it describes as a "ticking time bomb" for cancer patients.
According to the RCR, pledges to reduce cancer waiting lists are unattainable without an increase in staff.
Their reports on oncology and radiology staffing shortages highlight that these issues are creating a "postcode lottery" for patients, with smaller cancer centres more likely to report concerns over workforce shortages.
The report on oncologists, or cancer doctors, indicates that 70 per cent of heads of service at cancer centres are worried about the impact of workforce shortages on patient safety. Furthermore, 23 per cent reported that they were unable to hire additional staff due to recruitment freezes.
One consultant clinical oncologist told the RCR: 'Safe delivery of cancer treatment is becoming increasingly impossible.'
Another said: 'Our waiting times for breast radiotherapy are now the worst I have ever known in 20 years. Patients are waiting over four weeks to be seen … and then another eight weeks to start radiotherapy.'
Meanwhile, the report on radiologists – the specialists who use clinical images to diagnose, treat and manage medical conditions and diseases, including cancer – highlights how the radiology workforce grew by 4.7% in 2024, but demand for CT and MRI imaging grew by 8%.
One consultant radiologist said: 'Patients are waiting longer than they should … and we have had several delayed cancer diagnoses as a result.'
The RCR has predicted that by 2029 there will be a 39% shortfall in the number of radiologists in the UK, and there will be a 19% shortfall in oncologists.
The college said workforce pressures are also forcing staff to take early retirement – the average age of radiologists leaving the NHS workforce is now just 50 years old, down from 55 in 2020, and the average age a consultant clinical oncologist leaves is now 54, from 59 in 2022.
Dr Katharine Halliday, president of the Royal College of Radiologists, said: 'Patients are being failed by a chronic lack of radiologists and oncologists.
'Despite the best efforts of NHS staff, there aren't enough doctors to ensure prompt, safe and effective care – and the outlook is bleak.
'We are doing all we can to boost productivity, but there's a limit to how far we can go. The reality is we simply don't have enough staff.
'Any credible plan to cut waiting lists relies on having the headcount to meet the demand we face today, let alone tomorrow.
'The longer we delay action, the worse it gets. The government must train up more radiologists and oncologists to defuse this ticking time bomb for cancer diagnosis and treatment.'
Commenting on the report, Genevieve Edwards, chief executive of Bowel Cancer UK, said: '(Bowel cancer) is treatable and curable if diagnosed early, but too many patients are facing long delays to start their treatment after going to their GP with symptoms.
'These delays may lead to the cancer spreading, making it harder to treat successfully.
'To fix this problem we must address the longstanding shortage of staff and equipment to deliver diagnostic and treatment services and meet the growing demand.'
Chiara De Biase, from Prostate Cancer UK, added: 'These latest findings are extremely concerning. Prostate Cancer UK would urge the Government to look at the RCR's recommendations to ensure the workforce required to diagnose and treat the most common cancer in England are in post, trained and supported to execute their roles to best of their abilities.'
Claire Rowney, chief executive at Breast Cancer Now, added: 'The worrying reality right now is that staff shortages continue to deny far too many people with breast cancer a timely diagnosis and quick access to potentially lifesaving treatments that they should be able to count on.
'Instead, they're facing long, anxious waits for this care.
'We recognise the intense challenges facing the health service, and the tireless efforts of its hard-working staff.
'However, this situation has to be addressed and the Government's upcoming national cancer plan for England offers a vital opportunity to bring about this much-needed change.'
A Department of Health and Social Care spokesperson said: 'This Government inherited a broken NHS where too many cancer patients are waiting too long for treatment. But through our Plan for Change, we are determined to tackle delays, diagnose cancer earlier and treat it faster.
'We are delivering 40,000 more appointments every week, investing £1.5 billion in both new surgical hubs and AI scanners, rolling out cutting-edge radiotherapy machines to every region in the country, and backing our radiologists and oncologists with above-inflation pay rises for the second year in a row.
'Later this year we will also publish a refreshed workforce plan to ensure the NHS has the right people in the right places to deliver the care patients need.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
8 minutes ago
- The Independent
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'


Reuters
38 minutes ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.